[8-K] Kalaris Therapeutics, Inc. Reports Material Event

Rhea-AI Filing Summary

Kalaris Therapeutics, Inc. furnished a press release announcing its financial results for the quarter ended June 30, 2025. The press release is provided as Exhibit 99.1 to this Form 8-K and is incorporated by reference.

This Current Report itself does not include any financial figures or operating metrics; it states that the information in the press release is being furnished and shall not be deemed "filed" under the Exchange Act. The filing was submitted on behalf of the company and is signed by Chief Executive Officer Andrew Oxtoby. Readers must consult Exhibit 99.1 for the detailed results.

Insights

Financial Analyst

TL;DR: Routine earnings disclosure furnished via press release; no numbers in the 8-K, so impact depends on Exhibit 99.1 content.

The filing is a standard Item 2.02 disclosure that a press release with quarterly results has been furnished as an exhibit. Because the 8-K does not contain revenue, EPS, cash position, or guidance, investors cannot assess financial performance from this filing alone. Materiality hinges entirely on the contents of Exhibit 99.1; the 8-K primarily documents compliance with disclosure rules and preserves the company's obligation to make the results public.

Corporate Governance Expert

TL;DR: Governance and disclosure practices appear routine and compliant; furnishing rather than filing limits legal exposure.

The report follows common practice of furnishing a press release under Item 2.02 and explicitly states the exhibit is "furnished" not "filed," which is consistent with limiting Section 18 liability. The CEO signature is included, indicating proper authorization. There are no disclosures here about material contracts, executive changes, or governance actions; the document solely documents the issuance of the press release.

false 0001754068 0001754068 2025-08-13 2025-08-13

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): August 13, 2025

KALARIS THERAPEUTICS, INC.

(Exact name of registrant as specified in its charter)

Delaware		001-39409		83-1971007
(State or other jurisdiction of incorporation)		(Commission File Number)		(I.R.S. Employer Identification No.)

Kalaris Therapeutics, Inc.

628 Middlefield Rd.

Palo Alto, California 94301

(Address of principal executive offices, including zip code)

(650) 249-2727

(Registrant’s telephone number, including area code)

Not applicable

(Former Name or Former Address, if Changed Since Last Report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class		Trading Symbol(s)		Name of each exchange on which registered
Common Stock, $0.0001 par value per share		KLRS		The Nasdaq Global Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition.

On August 13, 2025, Kalaris Therapeutics, Inc. (the “Company”) issued a press release announcing the Company’s financial results for the quarter ended June 30, 2025. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.

The information in this Form 8-K, including Exhibit 99.1 attached hereto, is being furnished and shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing by the Company under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such filling.

Item 9.01 Financial Statements and Exhibits.

(d) Exhibits

Exhibit No.		Description
99.1		Press Release issued by Kalaris Therapeutics, Inc. on August 13, 2025
104		Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

				KALARIS THERAPEUTICS, INC.
Date: August 13, 2025				By:		/s/ Andrew Oxtoby
				Name:		Andrew Oxtoby
				Title:		Chief Executive Officer

FAQ

What did Kalaris Therapeutics (KLRS) disclose in this 8-K?

The company announced that it furnished a press release

Are the financial results included in this Form 8-K for KLRS?

No. The Form 8-K states the press release is being furnished and the filing itself contains no financial figures

Is the press release in this 8-K considered "filed" with the SEC?

No. The 8-K explicitly states the information, including Exhibit 99.1, is being furnished and shall not be deemed "filed" under the Exchange Act.

Where can investors find the detailed numbers for KLRS quarter ended June 30, 2025?

Investors should consult Exhibit 99.1 to the Form 8-K, which contains the press release with the detailed financial results.

Who authorized the 8-K filing for Kalaris Therapeutics?

The report is signed on behalf of the registrant by Andrew Oxtoby, Chief Executive Officer.